![David Adair](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Adair
Directeur/Bestuurslid bij Rediscovery Life Sciences AKI LLC
Oorsprong van het eerstegraads netwerk van David Adair
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Rediscovery Life Sciences AKI LLC
![]() Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC.
5
| Subsidiary | Medical/Nursing Services | 5 |
Rediscovery Life Sciences LLC
![]() Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC.
5
| Holding Company | Biotechnology | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met David Adair via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
PRA HEALTH SCIENCES, INC. | Miscellaneous Commercial Services | President | |
University of Notre Dame | College/University | Undergraduate Degree | |
University of Missouri | College/University | Undergraduate Degree | |
North Carolina State University | College/University | Undergraduate Degree | |
The Pennsylvania State University | College/University | Masters Business Admin | |
Council for Entrepreneurial Development
![]() Council for Entrepreneurial Development Miscellaneous Commercial ServicesCommercial Services Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC. | Miscellaneous Commercial Services | Director/Board Member | |
Rex Health Ventures LLC
![]() Rex Health Ventures LLC Investment ManagersFinance Rex Health Ventures LLC (Rex Health Ventures) is a venture capital subsidiary of Rex Strategic Innovations founded in 2012. The firm is headquartered in Raleigh, North Carolina. | Investment Managers | Private Equity Investor | |
Vascular Pharmaceuticals, Inc.
![]() Vascular Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vascular Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of diabetics. It provides new treatment options to individuals living with diabetic complications such as nephropathy. The company was founded by David R. Clemmons and Laura Maile in 2005 and is headquartered in Research Triangle Park, NC. | Pharmaceuticals: Major | Chief Executive Officer | |
The Fuqua School of Business | College/University | Masters Business Admin | |
UNC School of Law | College/University | Undergraduate Degree | |
KCBN Holding, Inc.
![]() KCBN Holding, Inc. MiscellaneousMiscellaneous KCBN Holding, Inc. provides compliance services to the healthcare sector. The company is headquartered in Kansas City, MO. | Miscellaneous | Director/Board Member | |
Evolution Research Group LLC
![]() Evolution Research Group LLC Miscellaneous Commercial ServicesCommercial Services Evolution Research Group LLC provides in-patient and out-patient clinical trial services to pharmaceutical companies. It specializes in psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency and hepatic impairment, and normal healthy volunteers. The company was founded in 2014 and is headquartered in New Providence, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
Advarra, Inc.
![]() Advarra, Inc. Miscellaneous Commercial ServicesCommercial Services Advarra, Inc. engages in the provision of integrated research compliance solutions. It offers institutional review board (IRB), institutional biosafety committee (IBC), and research quality and compliance consulting services. It also covers GxP/GCP auditing and compliance, regulatory, clinical quality and assurance, research administration and human research protection (HRP), and data protection and technology compliance. The company was founded in 1983 and is headquartered in Columbia, MD. | Miscellaneous Commercial Services | Chief Executive Officer | |
Basking Biosciences, Inc.
![]() Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Biotechnology | Chief Executive Officer | |
Mitochem Therapeutics, Inc.
![]() Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Pharmaceuticals: Generic | Director/Board Member | |
University of North Carolina at Chapel Hill | College/University | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 19 |
Sectoraal
Consumer Services | 8 |
Commercial Services | 7 |
Health Technology | 4 |
Finance | 3 |
Miscellaneous | 2 |
Operationeel
Director/Board Member | 14 |
Chief Executive Officer | 7 |
Undergraduate Degree | 4 |
Chairman | 3 |
President | 2 |
Sterkste connecties
Insiders | |
---|---|
Patrick K. Donnelly | 11 |
Richard J. Shea | 7 |
Anita Watkins | 6 |
Rick Schnellman | 3 |
Sunil Desai | 2 |
- Beurs
- Insiders
- David Adair
- Bedrijfsconnecties